Under the transaction, Bio-Rad paid €53m in cash to AbD Serotec, which offers over 15,000 antibodies, kits, as well as other accessories.

In addition, AbD Serotec has an ISO 9001 and ISO 13485 certified antibody production facility in the UK, as well as other facilities in Germany and the US.

Bio-Rad president and CEO Norman Schwartz said, "With AbD Serotec’s comprehensive catalog of antibodies, we are able to offer our customers total assay solutions that can be validated on many of our research platforms for western blotting, multiplex protein expression, ELISA, and cell sorting."